Linked Life Data

21246934

Source:http://linkedlifedata.com/resource/pubmed/id/21246934

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-1-20
pubmed:abstractText
All currently approved therapies for multiple sclerosis (MS) modulate systemic immune components prior to their entry into the central nervous system (CNS). Available data indicate they lack impact on the progressive phases of disease; the more potent systemic immune-directed agents predispose to development of infectious or neoplastic disorders. Development of new agents that enhance disease stage related efficacy and limit systemic toxicity will need to consider the underlying mechanisms related to each phase of the clinical disorder, namely relapses, remission, and progression. This report focuses on disease related mechanisms ongoing within the CNS that contribute to the different phases of MS and how these may serve as potential therapeutic targets. Such mechanisms include CNS compartment specific immunologic properties especially as related to the innate immune system and neural cell-related properties that are determinants of the extent of actual tissue injury and repair (or lack thereof).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0317-1671
pubmed:author
pubmed:issnType
Print
pubmed:volume
37 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S42-8
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
New directions in multiple sclerosis therapy: matching therapy with pathogenesis.
pubmed:affiliation
Neuroimmunnology Unit, Montreal Neurologic Institute, Montreal, Quebec, Canada.
pubmed:publicationType
Journal Article